Nasdaq Hearings Panel grants SLRX additional extension to regain listing compliance by August 2025

Decoy Therapeutics Inc.

Equity Standard compliance deadline extended to mid-August 2025 from late July.
Minimum Bid Price compliance deadline extended to late August 2025 from early August.
Company previously effected a reverse stock split within past year, affecting eligibility for standard compliance periods.
Failure to meet milestones could result in delisting from Nasdaq.
Company's common stock (SLRX) remains listed pending hearing process resolution.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.